Tandem Diabetes Care (TNDM) Depreciation & Amortization (CF) (2013 - 2026)

Tandem Diabetes Care's Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 4.48% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 5.83% YoY) and the FY2025 annual result came in at $17.7 million, up 6.38% from the prior year.
• Depreciation & Amortization (CF) was $4.5 million for Q1 2026 at Tandem Diabetes Care, roughly flat from $4.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $4.5 million in Q1 2026 and bottomed at $3.4 million in Q1 2023.
• A 5-year average of $4.0 million and a median of $4.1 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Peak annual rise in Depreciation & Amortization (CF) reached 20.04% in 2023, while the deepest fall reached 6.39% in 2023.
• Tandem Diabetes Care's Depreciation & Amortization (CF) stood at $3.6 million in 2022, then increased by 10.71% to $4.0 million in 2023, then rose by 5.31% to $4.2 million in 2024, then advanced by 5.89% to $4.5 million in 2025, then gained by 0.2% to $4.5 million in 2026.
• Business Quant data shows TNDM's Depreciation & Amortization (CF) at $4.5 million in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.